Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Vertex Pharmaceuticals ( (VRTX) ).
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals’ ALYFTREK™ for treating cystic fibrosis in individuals aged six and older with specific gene mutations. This approval marks a significant advancement for the company, highlighting its role in addressing genetic disorders and potentially expanding its market position in the cystic fibrosis treatment landscape.
More about Vertex Pharmaceuticals
YTD Price Performance: -2.52%
Average Trading Volume: 1,290,759
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $102.1B
For a thorough assessment of VRTX stock, go to TipRanks’ Stock Analysis page.
